# Atomera Inc: financial statements, quarterly

ATOM · Nasdaq · CIK 1420520 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atom.md) · [Financials](/companies/atom/financials.md) · [Filings](/companies/atom/filings.md) · [Insiders](/companies/atom/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/atom/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0001683168-24-007452.md) | [550 d](/filings/0001683168-25-001330.md) | [18.0](/filings/0001683168-25-003249.md) | [72.0](/filings/0001683168-25-005672.md) | [22.0](/filings/0001683168-25-007840.md) | [23.0 d](/filings/0001683168-26-001291.md) | [4.0](/filings/0001683168-26-003501.md) | [0.0](/filings/0001683168-26-006050.md) | [11.0](/filings/0001683168-25-007840.md) | [50.0 d](/filings/0001683168-26-001291.md) | [11.0](/filings/0001683168-26-003501.md) | [158](/filings/0001683168-26-006050.md) |
| Cost of revenue | $k | [0.0](/filings/0001683168-24-007452.md) | [28.0 d](/filings/0001683168-25-001330.md) | [33.0](/filings/0001683168-25-003249.md) | [74.0](/filings/0001683168-25-005672.md) | [3.0](/filings/0001683168-25-007840.md) | [13.0 d](/filings/0001683168-26-001291.md) | [0.0](/filings/0001683168-26-003501.md) | [62.0](/filings/0001683168-26-006050.md) | [128](/filings/0001683168-25-007840.md) | [131 d](/filings/0001683168-26-001291.md) | [126](/filings/0001683168-26-003501.md) | [26.0](/filings/0001683168-26-006050.md) |
| Gross profit | $k | [0.0](/filings/0001683168-24-007452.md) | [522 d](/filings/0001683168-25-001330.md) | [(15.0)](/filings/0001683168-25-003249.md) | [(2.0)](/filings/0001683168-25-005672.md) | [19.0](/filings/0001683168-25-007840.md) | [10.0 d](/filings/0001683168-26-001291.md) | [4.0](/filings/0001683168-26-003501.md) | [(62.0)](/filings/0001683168-26-006050.md) | [(117)](/filings/0001683168-25-007840.md) | [(81.0) d](/filings/0001683168-26-001291.md) | [(115)](/filings/0001683168-26-003501.md) | [132](/filings/0001683168-26-006050.md) |
| Research and development | $k | [3,305](/filings/0001683168-24-007452.md) | [2,992 d](/filings/0001683168-25-001330.md) | [2,858](/filings/0001683168-25-003249.md) | [2,589](/filings/0001683168-25-005672.md) | [2,759](/filings/0001683168-25-007840.md) | [2,823 d](/filings/0001683168-26-001291.md) | [3,255](/filings/0001683168-26-003501.md) | [3,004](/filings/0001683168-26-006050.md) | [3,304](/filings/0001683168-25-007840.md) | [2,740 d](/filings/0001683168-26-001291.md) | [3,457](/filings/0001683168-26-003501.md) | [3,287](/filings/0001683168-26-006050.md) |
| Operating income | $k | [(5,353)](/filings/0001683168-24-007452.md) | [(4,797) d](/filings/0001683168-25-001330.md) | [(5,034)](/filings/0001683168-25-003249.md) | [(4,630)](/filings/0001683168-25-005672.md) | [(4,800)](/filings/0001683168-25-007840.md) | [(4,872) d](/filings/0001683168-26-001291.md) | [(5,463)](/filings/0001683168-26-003501.md) | [(5,255)](/filings/0001683168-26-006050.md) | [(5,793)](/filings/0001683168-25-007840.md) | [(4,612) d](/filings/0001683168-26-001291.md) | [(6,324)](/filings/0001683168-26-003501.md) | [(6,759)](/filings/0001683168-26-006050.md) |
| Interest expense | $k | [47.0](/filings/0001683168-23-007564.md) | [43.0 d](/filings/0001683168-24-001031.md) | [39.0](/filings/0001683168-24-002847.md) | [35.0](/filings/0001683168-25-005672.md) | [30.0](/filings/0001683168-25-007840.md) | [25.0 d](/filings/0001683168-26-001291.md) | [21.0](/filings/0001683168-26-003501.md) | [18.0](/filings/0001683168-26-006050.md) | [12.0](/filings/0001683168-25-007840.md) | [9.0 d](/filings/0001683168-26-001291.md) | [4.0](/filings/0001683168-26-003501.md) | [1.0](/filings/0001683168-26-006050.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(5,039)](/filings/0001683168-24-007452.md) | [(4,580) d](/filings/0001683168-25-001330.md) | [(4,822)](/filings/0001683168-25-007840.md) | [(4,361)](/filings/0001683168-25-007840.md) | [(4,595)](/filings/0001683168-25-007840.md) | [(4,657) d](/filings/0001683168-26-001291.md) | [(5,209)](/filings/0001683168-26-006050.md) | [(4,967)](/filings/0001683168-26-006050.md) | [(5,573)](/filings/0001683168-25-007840.md) | [(4,425) d](/filings/0001683168-26-001291.md) | [(6,073)](/filings/0001683168-26-006050.md) | [(6,336)](/filings/0001683168-26-006050.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0001683168-24-007452.md) | not reported | [(0.19)](/filings/0001683168-25-003249.md) | [(0.16)](/filings/0001683168-25-005672.md) | [(0.17)](/filings/0001683168-25-007840.md) | not reported | [(0.17)](/filings/0001683168-26-003501.md) | [(0.17)](/filings/0001683168-26-006050.md) | [(0.17)](/filings/0001683168-25-007840.md) | not reported | [(0.17)](/filings/0001683168-26-003501.md) | [(0.17)](/filings/0001683168-26-006050.md) |
| Basic EPS | $ per share | [(0.20)](/filings/0001683168-24-007452.md) | not reported | [(0.19)](/filings/0001683168-25-003249.md) | [(0.16)](/filings/0001683168-25-005672.md) | [(0.17)](/filings/0001683168-25-007840.md) | not reported | [(0.17)](/filings/0001683168-26-003501.md) | [(0.17)](/filings/0001683168-26-006050.md) | [(0.17)](/filings/0001683168-25-007840.md) | not reported | [(0.17)](/filings/0001683168-26-003501.md) | [(0.17)](/filings/0001683168-26-006050.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [12.6](/filings/0001683168-23-007564.md) | [12.6](/filings/0001683168-25-001330.md) | [14.8](/filings/0001683168-24-002847.md) | [14.5](/filings/0001683168-24-005141.md) | [13.8](/filings/0001683168-24-007452.md) | [25.8](/filings/0001683168-26-001291.md) | [24.1](/filings/0001683168-25-003249.md) | [22.0](/filings/0001683168-25-005672.md) | [20.3](/filings/0001683168-25-007840.md) | [19.2](/filings/0001683168-26-006050.md) | [14.2](/filings/0001683168-26-003501.md) | [15.1](/filings/0001683168-26-006050.md) |
| Current assets | $m | [20.8](/filings/0001683168-23-007564.md) | [20.4](/filings/0001683168-25-001330.md) | [19.7](/filings/0001683168-24-002847.md) | [18.9](/filings/0001683168-24-005141.md) | [17.8](/filings/0001683168-24-007452.md) | [27.1](/filings/0001683168-26-001291.md) | [24.5](/filings/0001683168-25-003249.md) | [22.7](/filings/0001683168-25-005672.md) | [21.0](/filings/0001683168-25-007840.md) | [19.6](/filings/0001683168-26-006050.md) | [42.1](/filings/0001683168-26-003501.md) | [39.0](/filings/0001683168-26-006050.md) |
| Total assets | $m | [24.8](/filings/0001683168-23-007564.md) | [24.0](/filings/0001683168-25-001330.md) | [22.9](/filings/0001683168-24-002847.md) | [21.9](/filings/0001683168-24-005141.md) | [20.1](/filings/0001683168-24-007452.md) | [29.1](/filings/0001683168-26-001291.md) | [26.3](/filings/0001683168-25-003249.md) | [24.1](/filings/0001683168-25-005672.md) | [21.9](/filings/0001683168-25-007840.md) | [21.1](/filings/0001683168-26-006050.md) | [43.6](/filings/0001683168-26-003501.md) | [40.2](/filings/0001683168-26-006050.md) |
| Current liabilities | $m | [3.0](/filings/0001683168-23-007564.md) | [3.8](/filings/0001683168-25-001330.md) | [2.9](/filings/0001683168-24-002847.md) | [3.1](/filings/0001683168-24-005141.md) | [3.4](/filings/0001683168-24-007452.md) | [3.6](/filings/0001683168-26-001291.md) | [2.9](/filings/0001683168-25-003249.md) | [2.8](/filings/0001683168-25-005672.md) | [2.9](/filings/0001683168-25-007840.md) | [2.0](/filings/0001683168-26-006050.md) | [2.2](/filings/0001683168-26-003501.md) | [2.3](/filings/0001683168-26-006050.md) |
| Total liabilities | $m | [5.4](/filings/0001683168-23-007564.md) | [5.9](/filings/0001683168-25-001330.md) | [4.5](/filings/0001683168-24-002847.md) | [4.4](/filings/0001683168-24-005141.md) | [4.2](/filings/0001683168-24-007452.md) | [4.0](/filings/0001683168-26-001291.md) | [3.0](/filings/0001683168-25-003249.md) | [2.8](/filings/0001683168-25-005672.md) | [2.9](/filings/0001683168-25-007840.md) | [2.7](/filings/0001683168-26-006050.md) | [3.1](/filings/0001683168-26-003501.md) | [3.1](/filings/0001683168-26-006050.md) |
| Shareholders' equity | $m | [(19.5)](/filings/0001683168-24-007452.md) | [18.2](/filings/0001683168-26-001291.md) | [18.4](/filings/0001683168-25-007840.md) | [17.5](/filings/0001683168-25-007840.md) | [15.9](/filings/0001683168-25-007840.md) | [25.1](/filings/0001683168-26-006050.md) | [23.3](/filings/0001683168-26-006050.md) | [21.3](/filings/0001683168-26-006050.md) | [19.0](/filings/0001683168-25-007840.md) | [18.4](/filings/0001683168-26-006050.md) | [40.6](/filings/0001683168-26-006050.md) | [37.1](/filings/0001683168-26-006050.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,477) d](/filings/0001683168-24-007452.md) | [(2,908) d](/filings/0001683168-25-001330.md) | [(4,149)](/filings/0001683168-25-003249.md) | [(3,164) d](/filings/0001683168-25-005672.md) | [(2,895) d](/filings/0001683168-25-007840.md) | [(3,028) d](/filings/0001683168-26-001291.md) | [(4,782)](/filings/0001683168-26-003501.md) | [(3,505) d](/filings/0001683168-26-006050.md) | [(3,362) d](/filings/0001683168-25-007840.md) | [(3,222) d](/filings/0001683168-26-001291.md) | [(4,607)](/filings/0001683168-26-003501.md) | [(3,897) d](/filings/0001683168-26-006050.md) |
| Capital expenditure | $k | [13.0 d](/filings/0001683168-24-007452.md) | [0.0 d](/filings/0001683168-25-001330.md) | [0.0](/filings/0001683168-25-003249.md) | [6.0 d](/filings/0001683168-25-005672.md) | [0.0 d](/filings/0001683168-25-007840.md) | [8.0 d](/filings/0001683168-26-001291.md) | [4.0](/filings/0001683168-26-003501.md) | [10.0 d](/filings/0001683168-26-006050.md) | [13.0 d](/filings/0001683168-25-007840.md) | [22.0 d](/filings/0001683168-26-001291.md) | [0.0](/filings/0001683168-26-003501.md) | [16.0 d](/filings/0001683168-26-006050.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.3](/filings/0001683168-23-007564.md) | [23.7](/filings/0001683168-24-002847.md) | [24.7](/filings/0001683168-24-005141.md) | [25.3](/filings/0001683168-24-007452.md) | [26.0](/filings/0001683168-25-003249.md) | [26.5](/filings/0001683168-25-005672.md) | [27.4](/filings/0001683168-25-007840.md) | [30.2](/filings/0001683168-26-003501.md) | [30.4](/filings/0001683168-26-006050.md) | [31.1](/filings/0001683168-25-007840.md) | [35.3](/filings/0001683168-26-003501.md) | [38.6](/filings/0001683168-26-006050.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 39,024,042 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001683168-26-006050.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.